Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
Go back to Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform| (NASDAQ: AUTL) | Delayed: 1.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.86 | 52 Week High | $ | |||
| Open | $1.86 | 52 Week Low | $ | |||
| Day High | $1.86 | P/E | N/A | |||
| Day Low | $1.86 | EPS | $ | |||
| Volume | 503 | |||||
| THE BLACKSTONE GROUP L.P (NYSE: BX) | Delayed: 114.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $114.56 | 52 Week High | $32.07 | |||
| Open | $114.56 | 52 Week Low | $22.31 | |||
| Day High | $114.56 | P/E | 101.38 | |||
| Day Low | $114.56 | EPS | $1.13 | |||
| Volume | 82,711 | |||||
